PASG News and Press, Passage Bio Inc. From 12/17/21

– Independent Data Monitoring Committee recommends proceeding with two additional planned patient cohorts, which are now being recruited in parallel – Positive safety profile, including no serious adverse events, no complications related to intra-cisterna magna inj...

Exercised two additional options with University of Pennsylvania’s Gene Therapy Program aligned with company’s focus on CNS diseases with high unmet need Huntington’s disease, a fatal rare adult neurodegenerative disorder Canavan disease, a fatal rar...

New York, New York--(Newsfile Corp. - November 30, 2021) - Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Passage Bio, Inc. (NASDAQ: PASG) breached their fiduciary duties to shareholders. The investigation concerns p...

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. ...

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive office...

The following slide deck was published by Passage Bio, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Passage Bio, Inc. 2021 Q3 - Results - Earnings Call Presentation

On track to report initial safety and 30-day biomarker data for cohort 1 from Imagine-1 global Phase 1/2 trial for PBGM01 for the treatment of infantile GM1 in 4Q21 Activated multiple clinical sites across three global clinical programs, despite Covid-19 headwinds ...

PHILADELPHIA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m....

SIOX presented excellent data in its higher dose GM1 Gangliosidosis gene therapy program. Unfortunately, after hours that same day, its chief research and development officer announced he was moving on to another company. Investors seem to have latched on the latter news rather th...

PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in two upcoming conferences in October: ...